Fulminant meningococcal sepsis due to non-groupable Neisseria meningitidis in a patient receiving eculizumab

Hall, Victoria; Pai Mangalore, Rekha; He, Simon; Stevens, Kerrie; Trubiano, Jason A; Holmes, Natasha E; Howden, Benjamin P; Kwong, Jason C

doi:10.5694/mja17.01012

Topics

Infectious diseases

Clinical record

1 Austin Health, Melbourne, VIC
2 University of Melbourne, Melbourne, VIC

Correspondence: jason.kwong@unimelb.edu.au

Acknowledgements:

This study was funded through the State Government of Victoria Department of Health and Human Services, and the Australian Government Department of Health. Jason Trubiano, Benjamin Howden and Jason Kwong are supported by the National Health and Medical Research Council. Jason Kwong and Jason Trubiano are also supported by Australian Government Research Training Program Scholarships.

Competing interests:

No relevant disclosures.

1. Bond KA, Stevens K, Bulach D, et al. Rising incidence of invasive meningococcal disease caused by Neisseria meningitidis serogroup W in Victoria. Med J Aust 2016; 204: 265-266. <MJA full text>
2. Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine 2012; 30: B3-B9.
3. Benamu E, Montoya JG. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis 2016; 29: 319-329.
4. Health Canada. SOLIRIS (eculizumab) — increased risk of hemolysis or low hemoglobin with serogroup B meningococcal vaccination. Ottawa: Government of Canada; 2016. http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2016/60752a-eng.php (viewed June 2017).
5. McNamara LA, Topaz N, Wang X, et al. High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. MMWR 2017; 66: 734-737.

Online responses are no longer available. Please refer to our instructions for authors page for more information.